Predictive value of kynurenine pathway metabolites in patients with diabetic kidney disease
Acta Diabetologica · 14.07.2026 · 63 (10) · 1697-1706
DOI: 10.1007/s00592-026-02738-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Diabetologica, online erschienen am 14.07.2026. Verfasst von Mehmet Erdem und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Faculty of Medicine, Van Yuzuncu Yil University, Van, Turkey. Hauptthemen laut MEDLINE: Kynurenine, Diabetic Nephropathies, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Van Yuzuncu Yil University.
Abstract (Originalsprache)
AIM: Diabetic kidney disease (DKD) is a leading cause of end-stage kidney disease (ESKD). The kynurenine pathway, responsible for tryptophan metabolism, is linked to inflammation and renal injury. This study aimed to assess the predictive value of serum tryptophan and kynurenine pathway metabolites in diagnosing DKD and differentiating disease stages in patients with type 2 diabetes mellitus (T2DM). METHODS: A total of 164 individuals (134 with T2DM and DKD, 30 healthy controls) were included in this cross-sectional study. Serum tryptophan, kynurenine, kynurenic acid, quinolinic acid, picolinic acid, 3-hydroxykynurenine, and indoleamine 2,3-dioxygenase (IDO) levels were measured using ELISA. Analyses included ANOVA, correlation, logistic regression, and ROC curves. RESULTS: Tryptophan levels were significantly reduced, while kynurenine pathway metabolites were elevated in DKD patients. eGFR showed negative correlations with kynurenine, kynurenic acid, IDO, and 3-hydroxykynurenine. ROC analysis revealed kynurenic acid, IDO, and 3-hydroxykynurenine as accurate markers for DKD staging. Logistic regression identified IDO, kynurenine, and kynurenic acid as independent predictors. Kynurenine pathway metabolites, particularly kynurenic acid and IDO, exhibit high diagnostic performance for detecting and staging DKD. CONCLUSION: Kynurenic acid, IDO, and 3-hydroxykynurenine demonstrated strong discriminative capacity across DKD stages (AUC up to 0.951), and IDO was identified as an independent predictor of DKD. These metabolites may serve as complementary biomarkers for early risk stratification in DKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Faculty of Medicine, Van Yuzuncu Yil University, Van, Turkey.
- Department of Biochemistry, Faculty of Medicine, University of Van Yuzuncu Yil, Van, Turkey. hhakan.alp@yyu.edu.tr.
- Department of Internal Medicine, Lokman Hekim Hospital, Van, Turkey.
- Department of Nephrology, Department of Internal Medicine, Faculty of Medicine, Van Yuzuncu Yil University, Van, Turkey.
- Department of Medical Oncology, Faculty of Medicine, Van Yuzuncu Yil University, Van, Turkey.
- Department of Endocrinology, Department of Internal Medicine, Faculty of Medicine, Van Yuzuncu Yil University, Van, Turkey.
Förderung
- Van Yuzuncu Yil University
Zitieren
APA
Erdem, M., Alp, H. H., Düzen Oflas, N., Aydemir, O., Aydin, İ., Karaca, C., Sezgin, Y., Ebinç, S., Aldemir, M. N., & Alay, M. (2026). Predictive value of kynurenine pathway metabolites in patients with diabetic kidney disease. Acta Diabetologica, 63(10), 1697-1706. https://doi.org/10.1007/s00592-026-02738-w
Vancouver
Erdem M, Alp HH, Düzen Oflas N, Aydemir O, Aydin İ, Karaca C, et al. Predictive value of kynurenine pathway metabolites in patients with diabetic kidney disease. Acta Diabetologica. 2026;63(10):1697-1706. doi:10.1007/s00592-026-02738-w
BibTeX
@article{Erdem2026,
author = {Erdem, Mehmet and Alp, Hamit Hakan and Düzen Oflas, Nur and Aydemir, Ozan and Aydin, İbrahim and Karaca, Cebrail and Sezgin, Yasin and Ebinç, Senar and Aldemir, Mehmet Naci and Alay, Murat},
title = {Predictive value of kynurenine pathway metabolites in patients with diabetic kidney disease},
journal = {Acta Diabetologica},
year = {2026},
volume = {63},
number = {10},
pages = {1697--1706},
doi = {10.1007/s00592-026-02738-w}
}
EUVIMED